PMC:7377212 / 604-796 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T13","span":{"begin":19,"end":24},"obj":"NCBITaxon:10239"},{"id":"T14","span":{"begin":97,"end":105},"obj":"SP_7"},{"id":"T15","span":{"begin":115,"end":128},"obj":"CHEBI:35718;CHEBI:35718"},{"id":"T16","span":{"begin":163,"end":169},"obj":"NCBITaxon:4751"},{"id":"T59221","span":{"begin":97,"end":105},"obj":"SP_7"},{"id":"T9877","span":{"begin":115,"end":128},"obj":"CHEBI:35718;CHEBI:35718"},{"id":"T12804","span":{"begin":163,"end":169},"obj":"NCBITaxon:4751"}],"text":" respiratory tract viral infection; for example, a recent review found that 72% of patients with COVID-19 received antimicrobial therapy [3]. However, the risk of fungal co-infection, in parti"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T2","span":{"begin":1,"end":18},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"}],"text":" respiratory tract viral infection; for example, a recent review found that 72% of patients with COVID-19 received antimicrobial therapy [3]. However, the risk of fungal co-infection, in parti"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T13","span":{"begin":19,"end":34},"obj":"Disease"},{"id":"T14","span":{"begin":25,"end":34},"obj":"Disease"},{"id":"T15","span":{"begin":97,"end":105},"obj":"Disease"},{"id":"T16","span":{"begin":173,"end":182},"obj":"Disease"}],"attributes":[{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":" respiratory tract viral infection; for example, a recent review found that 72% of patients with COVID-19 received antimicrobial therapy [3]. However, the risk of fungal co-infection, in parti"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T6","span":{"begin":49,"end":50},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":" respiratory tract viral infection; for example, a recent review found that 72% of patients with COVID-19 received antimicrobial therapy [3]. However, the risk of fungal co-infection, in parti"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":115,"end":128},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"}],"text":" respiratory tract viral infection; for example, a recent review found that 72% of patients with COVID-19 received antimicrobial therapy [3]. However, the risk of fungal co-infection, in parti"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":19,"end":34},"obj":"http://purl.obolibrary.org/obo/GO_0016032"}],"text":" respiratory tract viral infection; for example, a recent review found that 72% of patients with COVID-19 received antimicrobial therapy [3]. However, the risk of fungal co-infection, in parti"}